Healing Peptides • Research Comparison

BPC-157 vs TB-500

📄 9 PubMed citations🔬 Preclinical — no human RCT

Last updated: October 2026

The two most popular healing peptides, head to head. In animal studies, BPC-157 is best known for gut and tendon repair, while thymosin beta-4 (TB-500's parent protein) is studied for cardiac repair and wound healing. Partly different mechanisms, and frequently stacked together.

🧪 Buy BPC-157 at Swiss Chems →
Code HIGHPEP10: 10% off regular-priced items
1
Human Study Cited
(Knee-Pain Chart Review)
8
References Listed
(See Sources)
0
FDA Approvals
(Neither Approved)

Track your vials and inventory on paper

Printable vial and inventory sheets for your own research records. Every value is entered by you. Free to build and preview; $5/month to unlock printing.

Stacking compounds? Check interactions first →

Build your tracker →

Side-by-Side: Key Facts

Feature BPC-157 TB-500
Full NameBody Protection Compound-157Thymosin Beta-4 Fragment
OriginGastric pentadecapeptide (15 amino acids)Synthetic fragment of thymosin beta-4 (full Tβ4 is a 43-amino-acid protein)
SourceDerived from human gastric juice proteinDerived from thymus gland protein
Primary TargetGut lesions, tendon repair (animal studies)Cardiac repair, skin and corneal wound healing (animal studies of Tβ4)
MechanismAngiogenesis, granulation tissue, NO-system interactionsActin binding, cell migration, angiogenesis, anti-inflammation
DosingNo human dose established in cited studies (animal dosing only)No human dose established in cited studies
RouteSubQ, IM, or OralSubQ or IM
Oral StabilityDescribed as a stable peptide; human oral absorption not measuredNo oral data in cited studies
Side EffectsNot characterized in the cited studiesNot characterized in the cited studies
FDA StatusNot approved; placed in FDA Category 2 (Sept 2023); nomination later withdrawn (current FDA list)Not approved, sold as a research peptide
Research LevelMostly animal studies; 1 human study cited here (PMID 34324435: retrospective chart review of 17 patients with multiple types of knee pain, 16 reached for phone follow-up; 11/12 given BPC-157 alone reported significant improvement). Not the only human work: the cited 2003 tendon paper (PMID 14554208) notes BPC 157 was then in clinical trials for inflammatory bowel disease.Mostly animal studies of full-length thymosin beta-4; the same knee-pain review also included patients given BPC-157 combined with TB4
Common StackOften combined with TB-500Often combined with BPC-157

Research Supplier

Research peptides from Swiss Chems, our affiliate vendor. Research peptides are unregulated. Check each product's certificate of analysis.

🧬 BPC-157 (5mg) Buy from Swiss Chems — check the product COA → Shop Now 🧬 TB-500 (10mg) Buy from Swiss Chems — check the product COA → Shop Now

Affiliate links support HighPeptides at no extra cost. Swiss Chems publishes third-party HPLC COAs for selected products (vendor-published, a claim to verify).

Different Pathways, Same Goal: Repair

BPC-157 and TB-500 are thought to promote healing through partly different molecular mechanisms, though both have been linked to new blood vessel formation (angiogenesis) in animal studies. The proposed differences are why they're so commonly stacked.

🧬
BPC-157: Gastric Pentadecapeptide

A 15-amino-acid peptide derived from a protein found in human gastric juice (BPC). In the rat studies cited here, BPC-157 is linked to angiogenesis (new blood vessel formation), granulation tissue formation, and interactions with the nitric oxide (NO) system. A separate rat tendon-fibroblast study (PMID 21030672, not in the reference list below) reports that its effect on fibroblast migration is likely mediated by the FAK-paxillin pathway. Described as a stable peptide in the cited studies; oral bioavailability in humans has not been measured.

Angiogenesis Granulation Tissue NO System FAK-Paxillin (cell study)
💪
TB-500: Thymosin Beta-4 Fragment

A synthetic fragment of thymosin beta-4 (Tβ4), a 43-amino-acid protein naturally produced in the thymus and found in most human cells. In animal and cell studies, Tβ4 binds actin and promotes cell migration, including the mobilization and differentiation of stem/progenitor cells. It also promotes new blood vessel formation (angiogenesis) in rodents and lowered inflammatory cytokine mRNA levels after corneal injury in mice.

Actin Regulation Cell Migration Anti-Inflammatory Angiogenesis

Healing Targets Compared

Based on the preclinical studies cited on this page. Ratings are our editorial summary of relative strength of animal-model evidence. No large controlled human trial results are cited for either compound for these indications. TB-500 ratings reflect studies of full-length thymosin beta-4; none of the cited studies tested the TB-500 fragment itself.

🦴 Tendon Repair (rat Achilles; no ligament data cited)
BPC-157
Limited (1 Rat Study + Cell Data)
TB-500
No Cited Data
🫁 Gut Healing & Protection
BPC-157
Review Only (No Primary GI Study Cited)
TB-500
No Cited Data
❤️ Cardiac Tissue Protection
BPC-157
Review Mention Only (No Primary Cardiac Study Cited)
TB-500
Limited (1 Mouse Study, Full Tβ4)
🔥 Inflammation (Animal Models)
BPC-157
Limited (Review Mentions + Tendon Histology)
TB-500
Limited (1 Mouse Corneal Study, Full Tβ4)

Why They're Frequently Combined

BPC-157 and TB-500 are among the most commonly stacked peptides in the research community. The rationale is mechanistic and theoretical: they are thought to act through partly different pathways.

Complementary Mechanisms Make the Case

BPC-157 is linked to new blood vessel formation (angiogenesis) and granulation tissue in rat studies. Thymosin beta-4 binds actin to drive cell migration and is also angiogenic in rodent studies, with reduced inflammatory signaling in a mouse corneal model. The theoretical case for stacking is that their mechanisms overlap only partly. No controlled study cited here has tested the combination.

🩸
Overlapping + Distinct Actions
Both have been linked to angiogenesis in animal studies. Tβ4 also binds actin to move repair cells; BPC-157 is linked to NO-system interactions and granulation tissue. The split is one of emphasis, not exclusivity.
🎯
Local + Systemic Action
BPC-157 is often described as acting more locally (especially near the injection site or gut), and TB-500 as distributing more systemically. This is a proposed difference, not one the cited studies compare.
⚡
Growth Factor Amplification
BPC-157 is linked to angiogenesis and granulation tissue in rat studies; thymosin beta-4 is linked to cell migration and stem/progenitor cell mobilization. Any amplifying effect of combining them is theoretical and untested in the cited studies.
🛡️
Combined Safety Unknown
Neither peptide's safety has been established in controlled human studies, and none of the cited sources report interaction data for the combination.

How They're Typically Used

Most of the primary studies cited on this page dosed animals (rats or mice). The one human report cited (PMID 34324435) is a small retrospective chart review of knee-pain patients who had BPC-157, alone or with TB4, injected into the knee. No human dose, frequency, or cycle length for either peptide is established by these sources, and neither has FDA-approved dosing. Always consult a physician.

BPC-157
Human Dose
Not established in cited studies
Cited Studies
Rat models (injection, intragastric, sponge implant)
Oral Option
Described as stable; human oral absorption not measured
Status
Research chemical — no approved dosing
TB-500
Human Dose
Not established in cited studies
Cited Studies
Full-length Tβ4 in rodents (e.g., topical on mouse corneas)
Oral Option
No oral data in cited studies
Status
Research chemical — no approved dosing

Side Effects: Limited Data

The studies cited on this page provide little adverse-event or tolerability data for either BPC-157 or TB-500. Side effects mentioned online are anecdotal community reports, not trial data, and long-term safety data in humans is extremely limited for both compounds.

Important context: A lack of reported side effects doesn't mean "proven safe." The side effect data that exists comes primarily from animal studies and community self-reports. Long-term effects, rare adverse events, and drug interactions are essentially unknown. Absence of evidence is not evidence of absence.

Regulatory Status & Availability

Neither peptide is FDA-approved. Both are sold as "research chemicals" (not for human consumption). The regulatory landscape has been shifting, particularly for BPC-157.

🧬
BPC-157
FDA placed BPC-157 on its Category 2 bulk substance list on September 29, 2023, restricting compounding pharmacies from producing it. FDA's current list shows the nomination was later withdrawn by the nominators, and on July 23, 2026 FDA's Pharmacy Compounding Advisory Committee discussed BPC-157 for the 503A bulks list. Still available from research peptide vendors.
💪
TB-500
Not FDA-approved. Available from research peptide vendors. Banned by WADA and most sporting organizations (performance enhancement).

FDA crackdown on BPC-157: On September 29, 2023, the FDA moved BPC-157 to Category 2 of its bulk drug substances list, effectively blocking compounding pharmacies from producing it for patients. This was a significant access change: previously many users obtained BPC-157 through compounding pharmacies with a doctor's prescription. Research peptide vendors remain the primary source, but these products are not regulated for human use and purity varies by vendor.

Decision Framework

Based on published research targets. This is not medical advice. Neither compound is approved for human therapeutic use. Many researchers use both simultaneously.

BPC-157 May Be Better For:
  • Gut healing: gastrointestinal lesions and ulcers (animal models)
  • Tendon injury (transected rat Achilles tendon model)
  • Oral route: sometimes used for gut targets; human oral absorption has not been measured
  • Organ lesions: liver, pancreas, heart (reviewed in animal models)
TB-500 May Be Better For (based on full-length Tβ4 studies):
  • Cardiac tissue protection: full-length Tβ4 aided repair after coronary artery ligation (mouse model)
  • Skin and corneal wound healing (rodent models)
  • Hair growth: reported in normal and aged rodents given full-length Tβ4
  • Scar and fibrosis reduction in wounds (animal data, reviewed)

Sources & References

[1] BPC-157 Angiogenesis (Rat Study)
Sikiric P, et al. The effect of pentadecapeptide BPC 157, H2-blockers, omeprazole and sucralfate on new vessels and new granulation tissue formation. J Physiol Paris. 1999;93(6):479-485. PMID: 10672992
[2] BPC-157 Tendon Healing
Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. PMID: 14554208
[3] BPC-157 GI Protection
Sikiric P, et al. The pharmacological properties of the novel peptide BPC 157 (PL-10). Inflammopharmacology. 1999;7(1):1-14. PMID: 17657443
[4] TB-500/Tβ4 Tissue Repair
Goldstein AL, et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. PMID: 22074294
[5] TB-500/Tβ4 Cardiac Repair
Bock-Marquette I, et al. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. PMID: 15565145
[6] TB-500/Tβ4 Wound Healing
Philp D, et al. Thymosin beta 4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-115. PMID: 15037013
[7] TB-500/Tβ4 Anti-Inflammatory
Sosne G, et al. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002;74(2):293-299. PMID: 11950239
[8] BPC-157 Knee Pain (Human Chart Review)
Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PMID: 34324435

The Bottom Line

What the Research Shows
  • BPC-157 has preclinical (animal) data for gut lesions and tendon healing
  • Thymosin beta-4 (TB-500's parent protein) has preclinical data for cardiac repair in mice and skin and corneal wound healing in rodents
  • Limited human data: PMID 34324435 — a retrospective chart review of 17 patients with multiple types of knee pain, 16 of whom were reached for phone follow-up; 11/12 given intra-articular BPC-157 alone reported significant improvement, no adverse events. The remaining patients received BPC-157 combined with TB4. No standardized outcome measures were used.
  • Partly different mechanisms (BPC-157: NO-system interactions; Tβ4: actin binding and cell migration; both angiogenic in animal studies) are the theoretical case for stacking
  • BPC-157 is described as a stable peptide, but human oral bioavailability has not been measured
  • Human safety and tolerability data are minimal for both
  • The BPC + TB stack is a common combination, but no controlled study of the combination is cited here
Keep in Mind
  • Neither is FDA-approved. Both are sold as research chemicals only
  • Most data comes from animal studies: the only human data cited is one small, uncontrolled knee-pain chart review (PMID 34324435), mostly BPC-157 alone plus a few patients on BPC-157 + TB4. No large controlled trial results are cited for either.
  • BPC-157 was placed on FDA Category 2 list in September 2023 (nomination later withdrawn), restricting compounding access
  • TB-500 is banned by WADA: tested athletes cannot use it
  • Research peptide purity varies wildly: third-party testing (e.g., Janoshik) is essential
  • Long-term safety data in humans is effectively nonexistent for both
Affiliate Vendor

Research-Grade Peptides

Research peptides are unregulated and not approved for human use. Review each product's certificate of analysis before buying.

Browse Swiss Chems →
Code HIGHPEP10: 10% off regular-priced items

Affiliate links support HighPeptides at no extra cost.

📚

Want the Complete Protocol Guide?

Dosing schedules, interaction warnings, and cycle protocols for 20+ compounds, all in one place. For BPC-157 and TB-500, no human study cited here establishes a dose, frequency, or cycle length.


Get the Guide: $19 (normally $29) →
The Peptide Buyer’s Playbook ($19)
Important Disclaimer

This page is for educational and informational purposes only. It is not medical advice. Neither BPC-157 nor TB-500 is FDA-approved for human use. Both are sold as research chemicals only. BPC-157 was placed on the FDA's Category 2 bulk drug substances list in September 2023, effectively blocking compounding pharmacy production; FDA's current list shows that nomination as withdrawn. TB-500 is banned by WADA and most sporting organizations. Most published research is preclinical (animal studies) — no large controlled human trial results are cited here for either compound. Dosing information reflects research protocols, not medical recommendations. Research peptide purity and identity are not guaranteed by vendors. Always consult a qualified healthcare provider. HighPeptides does not sell peptides or endorse their use outside of legitimate research settings.

📘

Get the Free 2026 Peptide Protocol Stack

Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.